# A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

> **NCT03575351** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 184 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** Standard of Care
- **GENETIC:** JCAR017

## Key facts

- **NCT ID:** NCT03575351
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-10-23
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575351, "A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03575351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*